Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27384356 | 0.85 | SMN1; SMN2 (0.40) | EPHX2CYP2C9CYP2J2SMN1; SMN2CYP2C19 | |
| SCHEMBL27384652 | 0.85 | SMN1; SMN2 (0.41) | EPHX2CYP2C9CYP2J2SMN1; SMN2CYP2C19 | |
| SCHEMBL27384658 | 0.82 | HTT (0.46) | EPHX2SMN1; SMN2 | |
| SCHEMBL27384690 | 0.80 | BTK (0.40) | EPHX2CYP2C9SMN1; SMN2CYP2C19RAB9A | |
| SCHEMBL27384453 | 0.78 | SMN1; SMN2 (0.40) | EPHX2CYP2C9CYP2J2SMN1; SMN2CYP2C19 | |
| SCHEMBL27383947 | 0.78 | RAB9A (0.55) | EPHX2SMN1; SMN2CYP2C19RAB9AGRIN2B | |
| SCHEMBL30920540 | 0.77 | MEN1 (0.40) | RAB9A | |
| SCHEMBL30920641 | 0.77 | MEN1 (0.40) | RAB9A | |
| SCHEMBL27382911 | 0.76 | RAB9A (0.42) | SMN1; SMN2RAB9AGRIN2B | |
| SCHEMBL27383268 | 0.76 | RAB9A (0.61) | SMN1; SMN2CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |